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The first biofluid markers developed for Alzheimer’s disease (AD) used targeted 
approaches for discovery. These initial biomarkers were directed at key protein constit-
uents of the hallmark brain lesions in AD. Biomarkers for plaques targeted the amyloid 
beta protein (Aβ) and for tangles, the microtubule-associated protein tau. Cerebrospinal 
fluid levels of Aβ and tau have excellent diagnostic utility and can be used to monitor 
aspects of therapeutic development. Recent research has extended our current concepts 
of AD, which now include a slow buildup of pathology during a long pre-symptomatic 
period, a complex cascade of pathological pathways in the brain that may accelerate 
once symptoms develop, the potential of aggregated proteins to spread across brain 
pathways, and interactions with vascular and other age-associated brain pathologies. 
There are many potential roles for biomarkers within this landscape. A more diverse 
set of biomarkers would provide a better picture of the staging and state of patho-
logical events in the brain across the stages of AD. The aim of this review is to focus 
on methods of biomarker discovery that may help to expand the currently accepted 
biomarkers. Opportunities and approaches for targeted and non-targeted (or −omic) 
biomarker discovery are highlighted, with examples from recent studies. How biomarker 
discoveries can be developed and integrated to become useful tools in diagnostic and 
therapeutic efforts is discussed.
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iNTRODUCTiON
Biomarkers have many potential uses in Alzheimer’s disease (AD), related neurodegenerative 
disorders and brain aging. Initial efforts to develop diagnostic biomarkers for AD were focused 
on the hallmark pathological lesions of senile plaques and neurofibrillary tangles. Amyloid beta-
protein (Aβ), an integral component of plaques, and the microtubule-associated protein tau, the 
major protein found in tangles, were detected in cerebrospinal fluid (CSF). Sensitive enzyme-
linked immunosorbent assays (ELISAs) were developed to selectively detect pathogenic forms of 
Aβ (Aβ42) and tau, with the later advent of assays for phosphorylated forms of tau (P-tau) (1–3). 
Different phosphor-epitopes of tau have been identified in CSF and are increased in AD, including 
tau phosphorylated at threonine181 (the form most commonly measured), serine 199, and serine 
FiGURe 1 | Biomarker discovery for Alzheimer’s disease – approaches.
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231 (4). Increased levels of P-tau are more specific for AD than 
other dementias and may add value in differential diagnosis (4, 
5). The profile of decreased Aβ42 and increased total tau and 
P-tau in CSF has high diagnostic value for AD (6) and has been a 
mainstay of AD biomarker research. Changes in CSF biomarkers 
are apparent in early symptomatic stages of AD, such as mild 
cognitive impairment (MCI) (7), and also occur pre-sympto-
matically (8). In these settings, the core biomarkers can provide 
prognostic information, for example, which patients with MCI 
may progress to AD dementia (7, 9–11). Also, studies have shown 
that patients with MCI or AD with higher baseline levels of CSF 
tau or P-tau (12, 13), and more recently higher baseline levels 
of the postsynaptic protein neurogranin (14) may show more 
rapid progression. This indicates the value of CSF biomarkers for 
predicting progression, e.g., for prognosis in preclinical stages of 
AD. Many forms of A-beta exist in CSF, and profiling N-terminal 
truncated forms was shown to increase prognostic value in MCI 
in one study (15).
Several themes that have emerged from AD research highlight 
the increased need for biomarkers, and also set the stage for how 
they may be used. First, AD is now viewed as a chronic and slowly 
progressive disorder, with a long buildup of pathology that pre-
cedes symptoms by a decade or longer (16). Also, among people 
with late-onset AD, autopsy studies highlight the frequent co-
occurrence of other brain pathologies, such as vascular changes 
(macro-infarcts, lacunes and micro-infarcts, amyloid angiopathy, 
arteriosclerosis, and microbleeds) and other protein aggregates 
(e.g., alpha-Synuclein and TDP43) (17, 18). These may contribute 
to dementia and can be difficult to detect during life. In patients 
with atypical presentations, such as younger onset of dementia, 
the clinical picture may not be clear, and biomarkers can provide 
pointers to underlying pathology. Finally, treatment interven-
tions for AD are shifting to earlier intervention, including stages 
of prodromal AD, where symptoms are mild, and most recently 
to prevention studies, where cognition falls within normal limits. 
Biomarkers have valuable roles to play in this pre-symptomatic 
stage to provide measures that may guide therapeutics. By meas-
uring several biomarkers in CSF through individual or multiplex 
assays, it may be possible to index a number of biochemical 
processes in the brain that are informative about AD and related 
neurodegenerative disorders simultaneously. This enhances the 
value of CSF sampling. This review will summarize the potential 
roles for biomarkers and how approaches to biomarker discovery 
can help to build a pipeline that will address these needs and 
inform risk assessment, diagnosis, and treatment (Figure 1).
SOURCeS OF FLUiD BiOMARKeRS
The most obvious source of biomarkers relevant to the brain is 
CSF, which bathes the brain and spinal cord. CSF biomarkers 
reflect overall brain biochemistry, and processes such as neuronal 
damage, synapse loss, and inflammation may result in detectable 
biomarker changes in CSF if they are extensive enough. CSF 
is sampled through the lumbar space and may have different 
concentrations of analytes compared to the ventricular CSF. 
Typically, analytes are more concentrated in lumbar CSF, as noted 
for Aβ40, Aβ42, and tau (19). The question of concentration 
gradients within the lumbar CSF arises for many analytes and 
needs to be studied – this is not a major problem for Tau, P-tau, 
and Aβ42. Blood derivatives, such as plasma and serum, are easier 
to access than CSF, but typically reflect the body as a whole. If a 
brain-specific protein crosses into the blood, it may be subject to 
dilution, the action of proteases, and clearance by the liver and 
kidney, rendering it difficult to detect. As a further complication, 
systemic features of AD, such as weight loss or lower physical 
activity may result in subtle changes in blood biomarker levels. 
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These are many of the reasons why it has been extremely difficult 
to identify a blood biomarker that directly reflects the state of 
neurodegeneration (20, 21).
There are other questions or areas where blood biomarkers 
may have utility. Some plasma or serum analytes may relate 
to traits that predispose to neurodegeneration, for example, 
biomarkers that may be influenced by susceptibility genes. If age 
or environmental risk factors related to dementia have systemic 
effects, then these may be evident through the analysis of blood 
biomarkers. Blood biomarkers are particularly helpful as meas-
ures of drug levels and can provide peripheral indices of target 
engagement. Blood cells, e.g., lymphocytes or leukocytes, may be 
used to derive immune signatures or measures of RNA expression 
that may be indices of susceptibility for AD. Plasma and blood 
biomarkers are influenced by genetic factors and a wide spectrum 
of environmental factors, for example, diet, systemic illness, 
and physical activity. A recent paper studied over 300 plasma 
analytes longitudinally in twins, and identified variability that 
could be attributed to all of these factors. These findings suggest 
that a search for peripheral markers for AD may be extremely 
complicated, because in addition to these variables, aging is yet 
another factor that may impact on levels of peripheral markers. 
Plasma levels of Aβ, including ratios between different forms 
of Aβ (such as the ratio of Aβ42/Aβ40) have been inconsistent 
across studies, are only weakly correlated with CSF levels of Aβ 
or with markers of amyloid brain imaging, and although they may 
have some predictive value for the development of AD, this is 
relatively low [reviewed in Ref. (22)]. Peripheral issue may be a 
source of pathological proteins if there are systemic features of a 
neurodegenerative disease. This has been identified in Parkinson’s 
disease (PD), where nerve endings can be stained for abnormal 
forms of alpha-synuclein in skin and salivary gland biopsy (23).
Regardless of whether a biomarker is measured in blood, CSF, 
or in biopsy material, data that shed light on how the biomarker 
is produced, released, cleared, and metabolized should be sought. 
To understand the biomarker comprehensively, it may require 
data from cell, model organism, and animal studies, as well as 
human biofluids and postmortem tissue. A recent development 
is the ability to study kinetics of CSF and plasma analytes by 
administering stable isotopes intravenously or orally to human 
subjects (24, 25). Examining the relationships between different 
types of biomarkers can also inform about pathogenetic pro-
cesses, for example, by correlating biofluid biomarker changes 
with neuroimaging markers. This also allows modeling of when 
the biomarker becomes abnormal and how it changes during the 
early course of AD (26).
eXPANDeD ROLeS FOR  
BiOMARKeRS iN AD
There are many potential roles of biomarkers for AD and neu-
rodegenerative disorders (Table  1). New biomarker discovery 
efforts need to take into consideration the current landscape 
of AD diagnosis and treatment efforts. The clinical diagnosis 
of typical AD by experts is often highly accurate; therefore, 
diagnostic biomarkers should be sensitive enough to help in 
early diagnosis, e.g., at stages of MCI or prodromal AD (27, 28). 
Because the sensitivity of CSF Aβ42, tau, and P-tau to discrimi-
nate prodromal AD from cognitively normal individuals is high, 
it may be challenging for additional biomarkers to improve on 
this. The differential diagnosis of unusual or atypical cases is a 
situation where biomarkers may clearly augment clinical judg-
ment. Evaluating whether non-AD pathology may be present is 
an important question, particularly in elderly individuals with 
cognitive problems, and additional biomarkers could be helpful 
if they inform about processes, such as alpha-Synuclein, TDP-43, 
or vascular brain pathology. Mixed pathology is often present in 
the brains of elderly individuals with dementia, and a biomarker 
panel that allowed clear prediction of the types of underlying 
pathology would be useful.
Therapeutic efforts for AD are shifting to earlier intervention, 
including studies of secondary prevention, and even primary 
prevention in people with genetic predisposition. Potential uses 
of CSF biomarkers in clinical trials for AD and PD were recently 
reviewed in detail (46). Neuropathology and clinical research 
have shown that there are preclinical stages of AD during which 
amyloid and tau pathology accumulates, before the onset of 
memory decline (47). This provides an opportunity to start 
treatment interventions with the goal of delaying the onset of 
AD. Changes in biomarkers may provide a clearer early readout 
from prevention studies than changes in cognitive measures. 
Biomarkers are critical to identifying the presence of amyloid or 
tau brain pathology in this situation. For studies of early inter-
vention, screening biomarkers, e.g., blood tests, that can improve 
the likelihood of detecting pathological brain changes through a 
more definitive test, such as molecular brain imaging and lumbar 
puncture, would be a great asset.
Biomarkers may help to improve the understanding of risk 
factors and mechanisms of disease. One would expect that 
causative or susceptibility genetic factors should be easy to link 
to biomarkers in biofluids. This has only been demonstrated 
in a few instances. For example, in AD, the APOE e4 allele has 
not yet been associated with a unique biomarker profile but 
modulates levels of the ApoE protein (48, 49). Inflammation 
plays a role in AD and other neurodegenerative disorders, and 
genetic variants related to the TREM2 gene increase the risk of 
AD and other dementias (50). In CSF, levels of a secreted soluble 
form of TREM were recently found to be decreased in AD (51). 
Other inflammatory biomarkers, such as secreted cytokines and 
chemokines, are unchanged or slightly increased in CSF in AD 
(52, 53). CSF biomarkers have been used as endophenotypes to 
discover genetic variants related to their levels, for example, CSF 
tau in AD (39), and CSF biomarkers related to inflammation 
(54). Genetic forms of non-AD dementia have provided clues 
for novel biomarkers. For example, inherited forms of fronto-
temporal dementia (FTD) due to mutations in the progranulin 
gene result in haplo-insufficiency with decreased production of 
granulin. Correspondingly, levels of granulin in plasma and CSF 
are markedly (and diagnostically) decreased (55). Burgeoning 
research on AD pathology has identified abnormalities in many 
biological processes, and it is likely that many pathogenic steps 
and events are occurring in a cascade (56). It may be feasible to 
develop biomarkers that can help to track many of these events, 
TABLe 1 | Roles for fluid biomarkers in Alzheimer’s disease.
Roles in diagnosis, staging, and 
prognosis
examples of biofluid markers Comments Reference
Screening or diagnosis with a blood 
test
Plasma Aβ42/Aβ40 Weak predictive value Toledo et al. (22)
Not diagnostic
Multi-analyte test panels, e.g., phospholipids Initial good discrimination, needs replication Mapstone et al. (29), 
Sattlecker et al. (30)Multi-analyte protein screening (e.g., Somascan)
Plasma t-Tau Slight increase in AD; much overlap Zetterberg et al. (31)
Auto-antibody profile; peptoids Needs replication Reddy et al. (32), 
Nagele et al. (33)
Diagnosis of AD vs. control CSF Aβ42, t-Tau, P-Tau Validated extensively Skillbäck et al. (5)
Diagnosis of AD pathology at 
prodromal or MCI stage
CSF Aβ42, t-Tau, P-Tau Validated extensively Mattsson et al. (7)
Differential diagnosis CSF Aβ42, t-Tau, P-Tau Validated extensively Skillbäck et al. (5)
Predict progression, e.g., from 
control to AD, MCI to AD, and rate 
of progression in AD
High levels of CSF t-Tau, P-Tau Validated extensively Shaw et al. (10)
Ratios e.g., Aβ42/t-Tau
Low CSF Aβ42
Aβ42 alone does not predict AD progression 
rate
N-terminal truncated CSF Aβ42 MCI progression Vanderstichele et al. 
(15)
Neurogranin MCI progression Kvartsberg et al. 
(14)
YKL40 MCI progression, control progression when 
combined with Aβ42
Craig-Schapiro et al. 
(34)
Visinin-like protein-1 MCI progression; control progression 
especially when combined with Aβ42
Tarawneh et al. (35)
Diagnosis of non-AD disorders Few specific markers, but ratios and patterns help,  
e.g., very high tau in CJD; ratio of P-tau/T-tau in  
FTLD-tau; high neurofilament-L levels in vascular 
cognitive impairment, PSP and FTLD
Skillbäck et al. (36), 
Hu et al. (37)
α-Synuclein Decreased in Parkinson’s but sensitivity is 
not diagnostically useful
Parnetti et al. (38)
Understand genetic and other risk 
factors
CSF t-Tau, P-tau, Aβ42 ApoE protein, clusterin, 
inflammatory cytokines TREM-2
Genes or SNPs associated with AD genetic 
risk may relate to levels of CSF biomarkers
Cruchaga et al. (39)
Markers of pathobiology Neurogranin, SNAP-25 Many other potential pathways and 
processes may be reflected in CSFSynaptic damage Visinin-like-protein-1; t-Tau
Neuronal damage NFL
Axonal tracts Cytokines, chemokines, c3, YKL-40
Inflammation
Blood–brain barrier integrity and 
small vessel CNS ischemia
CSF: serum albumin ratio, IgG index, MMP 2, 3, and 9; 
NFL
Altered in vascular cognitive impairment Rosenberg et al. 
(40)
Roles in therapeutics examples Comments Reference
Preclinical drug development Aβ42, t-Tau, P-Tau Can be used to evaluate compounds in cell 
and animal models
Liu et al. (41), 
Jeppsson et al. (42)sAPPα and sAPPβ
Oligomeric forms of Aβ and Tau
Target engagement in 
pharmacodynamic studies
Aβ40 and 42 in CSF and plasma for gamma-secretase 
inhibitors
Has helped with dose finding Fleisher et al. (43)
sAPPα, sAPPβ, and Aβ for BACE inhibitors
Detailed studies of synthesis and 
clearance
SILK studies for Aβ metabolism Used to characterize detailed 
pharmacodynamics of anti-Aβ therapeutics
Bateman et al. (24)
Patient selection or stratification CSF Aβ42, t-Tau, P-tau Enroll patients with AD signature Coric et al. (44)
Identify toxicity Increases in CSF biomarkers of neuronal damage or of 
inflammation
Van Gool et al. (45)
Provide biological support for 
treatment effect
Changes in CSF Aβ-related biomarkers indicating target 
engagement and of t-Tau, P-Tau, or synaptic markers 
such as neurogranin in a direction indicating reduction of 
neurodegeneration
Changes in a group of markers could 
support anti-amyloid therapeutics
This table is not intended as a comprehensive listing, but shows representative biomarkers that can aid in diagnostic or therapeutic efforts. The biomarkers in this table are discussed 
in the text. The majority of markers are proteins discovered through candidate approaches, but there is room for an expanded suite of markers using diverse discovery approaches 
to improve our understanding of AD.
t-Tau, total tau levels; α-Syn, alpha-Synuclein; sAPP, secreted amyloid protein precursor; NFL, neurofilament light; TREM2, triggering receptor expressed on myeloid cells 2; MBP, 
myelin basic protein; MMP, matrix metalloprotease; BACE, beta-site APP cleaving enzyme 1; SILK, stable isotope kinetic labeling; CJD, Creutzfeld–Jacob disease; PSP, progressive 
supranuclear palsy; FTLD, fronto-temporal lobar degeneration.
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for example, microglial activation, inflammation, synaptic dam-
age, and dysfunction (discussed later). This approach, together 
with neuroimaging methods, offers an opportunity to build a 
more complete picture of neurodegeneration in living patients at 
different stages of disease.
There are many potential therapeutic applications of biomark-
ers in AD. These typically have involved targeted biomarkers. 
During preclinical development, screening for gamma-secretase 
inhibitors and modulators and BACE inhibitors in cell and animal 
models have obtained their readout by using assays for the same 
secreted forms of Aβ that are used in AD diagnosis (57–59). These 
assays can be further applied to animal models and in human stud-
ies to identify target engagement and pharmacodynamic effects. 
A more detailed application is through CSF catheter placement 
to sample CSF during 24–36  h. This has been extended using 
stable isotope labeling kinetics (SILK) to estimate the fractional 
production and clearance rates of Aβ from CSF (24). In clinical 
trials, CSF biomarkers may be used to select patients or to stratify 
treatment. For example, in trials that aim to enroll patients with 
MCI due to AD, requiring a baseline CSF biomarker profile can 
increase confidence that the study population has symptoms 
due to AD rather than other causes. Target engagement may be 
demonstrated for certain types of amyloid-related interventions, 
in particular, secretase inhibitors. For example, gamma-secretase 
inhibitors that were studied in human clinical trials (43) and 
Beta-secretase inhibitors (60) showed robust effects in decreasing 
secreted forms of APP as well as Aβ in early phase studies, and 
the gamma-secretase inhibitor semagacestat showed plasma bio-
marker evidence of target activation in a phase 3 trial (61). Mass 
spectrometry (MS) characterization has identified a specific Aβ 
peptide signature after BACE inhibitor treatment (60). However, 
it is more challenging to show target engagement by antibodies 
directed against Aβ, because these bind Aβ and alter its levels in 
CSF and plasma. As novel drug targets are identified, efforts to 
identify companion biomarkers that help to identify immediate 
and downstream effects of drug action should be pursued.
Changes in levels of tau and P-tau in CSF have been examined 
as prototypic AD biomarkers of neurodegeneration or neuronal 
damage, with the hypothesis that neuroprotective or disease-
modifying drug effects may result in a decrease of these markers. 
It is likely that profiling biomarkers more broadly could be more 
informative. For example, biomarkers that index aspects of pre- 
and postsynaptic change, microglial activation, and astrocytic 
responses combined with neuroimaging could provide greater 
insights into the dynamics and interactions of neurons and glial 
cells in response to interventions. In efforts to make a claim to 
support drug efficacy, biofluid biomarkers are expected to play 
a supporting rather than a primary role. For example, if one 
of the effects of a drug treatment is to slow neurodegeneration 
enough to produce a meaningful cognitive readout, biomarker 
changes could be used to identify which disease-related path-
ways have been affected. To better understand events during 
neurodegeneration or disease progression, further exploration 
using non-targeted −omic approaches is worth pursuing. A 
complicated situation arises if biomarker changes are present in 
the absence of an appropriate clinical readout; this could indicate 
that the drug hit its target and influenced biomarkers but this 
is ineffective clinically, or that the changes in the biomarker are 
ambiguous. For example, CSF P-tau levels have been shown to 
decrease significantly in patients who received bapineuzumab, 
with a trend for total tau to decrease, but this did not correlate 
with clinical efficacy (62).
APPROACHeS TO DiSCOveR 
BiOMARKeRS iN BiOFLUiDS
Protein and peptide biomarkers in biofluids have formed the 
mainstay of clinical diagnostic tests in AD and other neurodegen-
erative disorders. As discussed above, despite over two decades of 
research, we have identified only a small number of fluid biomark-
ers for AD. The currently available biomarkers of CSF Aβ, tau, 
and P-tau have problems with measurement and standardization 
issues (63) that have hindered their routine and widespread use. 
The development of quality standards, a MS assay, and second-
generation assays for these analytes are likely to improve this 
situation. As yet there are no established biomarkers for other 
neurodegenerative disorders and for vascular cognitive impair-
ment. In view of the complexity of AD, the coexistence of mixed 
pathology in late-onset dementia, and the increasing emphasis 
for early diagnosis of AD and other neurodegenerative disorders, 
the search for additional biomarkers is highly warranted. One 
challenge is that CSF and plasma both contain proteins whose 
concentration spans several orders of magnitude, and almost all 
other proteins are overshadowed in concentration by albumin. 
Methods to identify novel biomarkers, in particular, proteomics, 
have improved, allowing post-translational modifications to 
be sought, and low abundance proteins (members of the “deep 
proteome”) to be detected. Two main strategies for biomarker 
discovery have emerged, namely, targeted or candidate biomarker 
discovery, and multiplex or −omic approaches.
Targeted Approaches to identify and 
Develop Protein and Peptide Biomarkers
The search for targeted or candidate biomarkers for AD met 
with significant early successes. Based on the expectation that 
abnormal forms of Aβ and tau could be found in CSF, methods to 
detect forms of these proteins in CSF and plasma were developed. 
Many important and complex steps have been involved in under-
standing and translating these hallmark AD biomarkers. To start, 
assays that selectively detected the longer and more aggregation-
prone form of Aβ, Aβ42, were required. Total levels of Aβ in CSF 
were unchanged in AD, and the paradox that levels of Aβ42 were 
selectively decreased in CSF in AD (1) has been “explained” by 
aggregation of this peptide within the brain, leaving less to diffuse 
into the CSF. CSF levels of Aβ42 were later found to correlate 
inversely with the extent of fibrillar brain amyloid deposition as 
measured by amyloid PET imaging (64, 65). Although increased 
levels of CSF tau were present in AD relative to controls, why this 
occurred was not clear – CSF tau is not a marker of tangle forma-
tion, but is increased in situations of significant neuronal damage, 
for example, after acute stroke (66) or in Creutzfeld–Jacob disease 
(36). Assays for specifically P-tau also showed increases in AD, 
and CSF P-tau had higher specificity for AD than did increases 
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of total tau. Only a few studies have tried to identify the forms of 
tau that are released into CSF. These were found to be N-terminal 
fragments of tau, with little if any of the full-length protein present 
(67, 68). The mechanisms of the release of tau into CSF remain 
unclear. Although converging data across many laboratories 
and studies have confirmed the profile of decreased Aβ42 and 
increased total and P-tau in CSF, cutoffs vary across laboratories 
(63, 69). Extensive quality control efforts have helped to decrease 
the variability. There are new efforts under way to develop fully 
automated assays for these key analytes, which will dramatically 
improve standardization.
Selecting a candidate biomarker has several advantages. 
Defined biochemical pathways and pathological mechanisms can 
help to relate the candidate to AD or to another neurodegenerative 
disorder, which may help to “make sense” of findings regarding 
the biomarker. Tools for detecting candidate biomarkers may be 
available, and sensitive detection methods can be developed. As 
a recent example, tau is released into CSF after neuronal injury. 
Increased levels of tau can be detected in plasma using ultrasensi-
tive assay methods and were found to be transiently increased in 
boxers after bouts (70). Post-translational modifications of can-
didate biomarkers may also be sought and may provide markers 
related to mechanisms of disease. For example, phosphorylation 
is important in regulatory and signaling pathways and has been 
implicated in altering the solubility and promoting aggregation 
of proteins. P-tau (4) and alpha-synuclein (71) are detectable in 
CSF and may provide insights into processes relevant to AD and 
PD, respectively.
Although CSF Aβ42 and tau reflect certain steps of pathology 
in the brain, much attention has focused on small oligomeric 
aggregates of these proteins. Evidence suggests that oligomeric 
forms of Aβ may be the culprits responsible for toxicity (72–74) 
and also suggests that oligomers and aggregates of tau are spe-
cies that contribute to neurodegeneration and correlate with 
cognitive loss in postmortem studies (75, 76). Also, aggregated 
or oligomeric forms of Aβ and tau may contribute to propagation 
of pathology (77). Despite the development of sensitive assays 
that can detect extremely low levels of Aβ oligomers, these have 
not been consistently or reliably identified in CSF in relation to 
AD (78, 79).
Several further examples of recent candidate biomarker 
discovery highlight the continued value of candidate approaches. 
A candidate approach led to the identification of the neuronal 
calcium sensor protein visinin-like protein-1 in CSF, and levels 
were found to be increased in AD relative to controls and pre-
dicted progression from non-demented to mild dementia (35) 
Similarly, a candidate approach was recently used to identify the 
dendritic protein neurogranin, which is involved in long-term 
potentiation and calcium regulation, and is decreased and mis-
localized in brain tissue in AD. After initial characterization in 
CSF by HPLC and MS methods an ELISA was developed. Levels 
of neurogranin were reported to be increased in CSF in AD, 
even at the stage of MCI (80), and predicted progression from 
prodromal AD to dementia, as well as rate of progression of MRI 
change in AD (14). As a second example, genetic studies have 
implicated variation in the gene that encodes TREM2 as a risk 
factor in some patients with late-onset AD and later for other 
neurodegenerative disorders [reviewed in Ref. (81)]. Studies into 
the biology of cells derived from people homozygous for TREM2 
mutations revealed impaired secretion of a cleaved fragment of 
TREM2. Decreased levels of this fragment were detected using 
an ELISA in CSF samples from patients with AD (51). Another 
example is the measurement of levels of granulin to identify 
people with mutations in the progranulin gene that predisposes 
to FTD. Progranulin mutations result in haplo-insufficiency and 
therefore people who carry mutations have a marked decrease in 
levels of secreted granulin in plasma and CSF (82).
One further example of an important application of CSF 
biomarkers relates to blood–brain barrier (BBB) integrity. An 
increased CSF:serum ratio of albumin is an established index 
used for many years as an indicator of loss of BBB integrity, and 
together with the IgG index and measurement of myelin basic 
protein levels, has been used as a diagnostic aid in multiple sclero-
sis. More recently, other markers of BBB integrity have emerged, 
particularly in relation to vascular cognitive impairment, and 
analysis of matrix metalloproteases and neurofilament-light 
levels have been proposed to supplement the albumin ratio and 
increase the diagnostic utility for subcortical small vessel disease 
(40).
A broader targeted approach to discovery is to multiplex 
known assays in combination [e.g., Luminex panels of assays of 
secreted proteins; multiple reagent monitoring (MRM) methods 
to examine selected panels of analytes with spiked in calibrator 
peptides for quantitation]. Several studies in AD have used arrays 
or multiplex ELISA-type assays for known secreted proteins to 
identify biomarkers in plasma and CSF (83, 84). Findings have 
been inconsistent, and different panels of plasma biomarkers 
have emerged from different studies, depending on analytical as 
well as biostatistical methods. Some of the analytes measured in 
these panels of secreted proteins in CSF showed correlations with 
cognitive test scores (85), or neuroimaging changes (86) although 
a validated panel of markers capable of tracking progression in 
AD has not yet emerged. Data from these studies were used to 
examine genetic variation associated with CSF levels of 59 pro-
teins, and there were associations for proteins involved in inflam-
matory signaling (54). There are no validated CSF biomarkers for 
most non-AD dementias, although patterns of biomarkers, such 
as CSF P-tau181/total tau ratio, may be helpful in discriminating 
tauopathies from TDP43-associated FTLD disorders (37).
Targeted biomarker approaches have some disadvantages. 
Their detection and analysis need specific reagents, e.g., antibod-
ies with high affinity, and antibodies against different regions are 
typically required to enable quantitative assays to be established 
and post-translational modifications to be analyzed. Finally, 
carrying out serial studies of candidate biomarkers and run-
ning individual assays to obtain multi-analyte data can be time 
consuming.
Highly Sensitive Assays
Many analytes detectable in plasma or CSF occur at low levels. 
This can pose a challenge to routine methods of analysis, such 
as ELISA. Recent technological refinements have resulted in 
ultrasensitive assay methods, capable of quantitation over low 
picomolar or femtomolar levels of analytes (87). For example, 
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immuno-PCR, in which an oligonucleotide is conjugated to a 
detector antibody in a sandwich format, then amplified, has been 
developed and refined to allowed multiplex assays (88). Another 
refinement, single molecule arrays (SIMOA), which divides 
samples into microwells and allows higher detection of signal to 
background, has been used to identify changes in plasma Aβ in 
patients who had experienced cardiac arrest (89) and increases 
in serum or plasma levels of tau in professional athletes after 
concussion (90), in combat-related traumatic brain injury (TBI) 
(91), and in patients with major brain trauma (92). Plasma levels 
of tau are slightly increased in AD compared to controls but are 
not diagnostically useful (31).The general theme that measuring 
multiple analytes may paint a more detailed and clearer picture 
applies to the setting of TBI: recent studies have shown that bio-
markers of neuronal, axonal, and astroglial injury appear acutely 
after the injury, and that axonal markers such as neurofilament 
protein persist longer in plasma and CSF than markers such as 
tau (93).
Non-Targeted Approaches to Protein and 
Peptide Biomarker Discovery
Non-targeted approaches to biomarker discovery typically 
involve multiplex and −omic methods, which range from 
analyzing 10 to 100 analytes to performing large-scale unbiased 
proteomic or metabolomic screens. These approaches have the 
advantages of providing coverage of a wide range of potential 
biomarkers, and of identifying novel markers and mechanisms 
that may not have been obvious from pathogenic mechanisms 
or pathology. Also, analyses of interactions between markers, 
and of how markers relate to biological pathways, can be under-
taken. There are several challenges to conducting, analyzing 
and interpreting large-scale −omic studies. For single analyte 
assays, a great deal of effort typically goes into development, 
standardization, and quantitation. By contrast, the analytes in 
large-scale −omic or similar methods may not be accurately 
quantified across their dynamic range. Both plasma and CSF 
have a few dominant proteins, in particular albumin, which 
are orders of magnitude higher in concentration than the vast 
majority of proteins and peptides. Methods to deplete the most 
dominant proteins are often used in −omic studies, but these 
preparation steps may alter the proteome. It is encouraging that 
test–retest proteomic analyses after immunodepletion of major 
proteins in CSF from subjects who underwent repeated lumbar 
punctures about 1 week apart provided evidence for a reasonably 
stable proteome (94). Detecting truncated forms of proteins or 
post-translational modifications may be more difficult in −omic 
studies using biofluids. Study design and data analysis need to be 
carefully considered to take proteomic studies from the stage of 
description or annotation to searching for group differences and 
the complex series of downstream steps that may lead to identi-
fication of candidate peptides and potential markers (95, 96). It 
is easy to identify false positive biomarker hits when hundreds 
of potential markers are analyzed and multiple comparisons are 
made, therefore separate cohorts for discovery and validation are 
essential. When interpreting findings, it is important to consider 
what factors may have contributed to the significant group of 
analytes. For example, vascular disease often coexists with AD, 
and vascular risk factors may be over-represented in AD patients 
compared to controls. Especially for proteomic studies of plasma, 
it is important to take factors such as hypertension, diabetes, 
weight loss, and decreased physical activity into account during 
data analyses. As an example of the promise of proteomic studies, 
recent promising results were reported in a large-scale effort to 
identify potential biomarkers related to aging through proteomic 
analysis of plasma, and strategies used in this project are sum-
marized in Ref. (96).
Many non-targeted large-scale proteomic studies of CSF 
have been conducted in AD. It is interesting to note that Aβ42 
and tau have not been detected as AD biomarkers in proteomic 
analyses of CSF. Early methods of separation, such as 2-dimen-
sional gel electrophoresis (2DGE), resulted in detection and 
annotation of members of the CSF proteome, but few consist-
ent markers specific for AD appeared. An extension of 2DGE 
called DIGE uses different fluorescent labels for biosamples 
from different groups of subjects (e.g., controls and those with 
disease) and allows for subtle differences to be identified. This 
has resulted in the discovery of a few novel biomarkers for 
AD, notably YKL40, a molecule secreted by astrocytes whose 
levels are increased in CSF in AD (34). MS methods remain the 
workhorse of proteomics and have been refined and improved 
in recent years. Analyses of CSF have continued to expand 
the catalog of proteins detectable in CSF, and a recent study 
identified and annotated over 2,500 proteins, each identified 
by at least 2 unique peptides [Ref. (97); database available at 
http://129.177.231.63/csf-pr/].
Technical improvements in MS have greatly improved the 
reproducibility of sample runs. Isobaric labeling of peptides, 
followed by a MS pipeline, can be used to compare samples 
from different groups of subjects. An approach that resembles 
the methods used in DIGE yielded several candidate peptide 
biomarkers for AD (98). Other approaches have allowed 
targeted quantitative analysis of selected peptides, as well as 
multiplexing (99, 100). By spiking in samples with heavily 
labeled known peptides as calibrators, a series of analytes may 
be analyzed quantitatively, termed MRM or selective reaction 
monitoring (SRM). For example, an exploratory proteomic 
study using CSF from patients with familial AD and controls 
yielded a set of novel candidate biomarkers (101), but these 
have not been replicated. Another study examined a panel of 
39 candidate CSF biomarkers using MRM, and identified 4 
that changed over 12  months with progression of AD (102). 
Recent studies of PD have explored whether a panel of analytes 
monitored using MRM may have value in diagnosis or relate to 
cognitive impairment (103). A pipeline for incorporating SRM 
methods into novel proteomic biomarker discovery has been 
proposed and its feasibility was demonstrated in a mouse cancer 
model (104). The sensitivity of MRM is much higher than that 
of untargeted proteomics, but it still is easier to quantify more 
abundant proteins, and antibody methods for highly sensitive 
assays have advantages for lower abundance analytes. Another 
analytical approach, immunoprecipitation followed by MS, 
allows differently processed forms of the same protein to be 
measured in biofluid samples. This targeted approach of MS has 
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been used for the analysis of different forms of Aβ peptides with 
a variety of different N- and C-terminal amino acids and has 
provided signatures of the effects of BACE inhibitors on APP 
processing (60).
Novel approaches to multiplex detection, such as the use 
of aptamer-based assays or antibody arrays, have allowed the 
profiling of hundreds to over one thousand analytes simultane-
ously from small starting volumes of biofluid sample, although 
the data generated are not truly quantitative (105). Aptamer 
approaches to screen for plasma biomarkers for AD are under 
way and have shown some initial promise. For example, in one 
study, a panel of 13 proteins predicted AD with an area under 
the ROC curve of 0.7 (30). Other studies that used this tech-
nology have found differences between patients with MCI and 
AD compared to controls, but the specific analytes that were 
most highly predictive have differed across studies (106, 107). 
Aptamer technology has also been applied to identify members 
of the plasma proteome that are changed with aging. In an aging 
twin study that was followed by replication in several other 
cohorts, 13 plasma proteins were identified that showed robust 
changes with aging, some of which are growth factors (108). 
About 26% of the variability of the markers measured in twins 
could be explained by a heritable component. Understanding 
more about the biology of analytes that are detected by 
aptamer-based tests, and conducting replication studies will be 
helpful to advance this novel approach to protein biomarker 
identification.
Non-Protein and “Unconventional” 
Biomarkers
Antibodies directed against novel antigens have been sought 
in serum or plasma as diagnostic markers for AD. Results have 
not always been consistent, and biomarkers have not yet been 
established using this method. One approach is to look for 
antibodies against pathogenic proteins, such as different forms 
of Aβ, e.g., by screening plasma or serum using micro-arrays. In 
recent examples, studies that screened for novel conformational 
forms of pathogenic proteins or unknown antigens that may be 
diagnostically altered in AD, PD, or other disorders have used 
auto-antibody and peptoid approaches [e.g., Ref. (32, 33, 109)]. 
Although initial hits emerged from these studies have not been 
replicated and the approaches have not yet matured into readily 
usable assays.
Metabolomic approaches measure small molecules that are 
substrates or products of metabolic processes. Two analytical 
methods are typically used, namely MS, which can identify large 
numbers of metabolites but has slow throughput, and magnetic 
resonance spectroscopy (MRS), which has higher throughput 
but lower sensitivity. Several recent small-scale studies have 
been able to distinguish patterns in CSF samples from AD 
patients and controls (110, 111). These studies will require 
extension and replication. Methods to standardize acquisition 
of metabolomics data are needed in order for these to be able to 
be readily used by reference laboratories. Increased statistical 
rigor and the need for extensive replication strongly need to 
be applied to metabolomic studies (112). Lipidomic analyses 
have also been applied to AD, with inconsistent findings. One 
recent study identified a panel of lipid-related biomarkers in 
plasma that predicted conversion to AD (29). Although clini-
cal assessment, sample handling, and biomarker analysis were 
carefully standardized in this study, the number of subjects who 
progressed from normal cognition to impairment was small. 
This panel of biomarkers has not yet been replicated. Another 
lipidomic study identified changes in long chain cholesteryl 
esters in plasma that discriminated patients with AD and con-
trols, but lacked replication cohorts (113). Careful study design 
with large enough numbers and replication cohorts are essential 
to make progress in this area. Also, robust assay platforms will 
need to be developed that will allow a set of lipidomic assays to 
be routinely run as a mature assay.
Exosomes are a subset of microvesicles and are released 
from cells under physiological and pathological conditions and 
circulate in body fluids. Exosomes are smaller than micropar-
ticles, and are usually defined as <100  nM in diameter. This 
small size poses a challenge to current methods of detection 
using flow cytometry. Exosomes arise from intracellular 
microvesicular bodies, whereas microparticles originate from 
the plasma membranes of cells or from apoptotic bodies. 
Exosomes may be implicated in neurodegenerative disorders 
in altered intercellular communication, for example, by 
transporting microRNA (miRNA), or by contributing to 
the spread of misfolded proteins (114). Methods to isolate 
exosomes have not been well standardized, and commercial 
kits yield mixed populations of exosomes and other particles. 
Extracellular vesicles, including exosomes, are found in CSF 
and their proteome has been characterized (115, 116). To date, 
there are no clear diagnostic markers that distinguish AD 
based on CSF exosomes, but much work is ongoing. Recent 
reports have isolated and analyzed exosomes in plasma, after 
using an immunopurification step to isolate a subset that have 
surface markers suggesting their neuronal origin, such as L1 
cellular adhesion molecule (L1CAM) (117, 118). Subsequent 
protein analyses using ELISA identified differences in levels 
of AD protein biomarkers of Aβ42 and tau (118) between AD 
and controls. These are promising initial findings, but much 
further work is needed to replicate and extend the findings. For 
example, it is unclear how exosomes might traffic from the CNS 
to the bloodstream, and therefore whether these truly reflect 
neuronal pathophysiology. Also, the multiple steps necessary to 
isolate exosomes and then assay their contents poses challenges 
to assay standardization.
MicroRNAs are small RNA species that control gene expres-
sion by binding to sets of target mRNAs and may play roles 
in intracellular communication. They can be isolated from 
exosomes or directly from biofluids. There are technical prob-
lems in quantifying levels of miRNAs, and the development of 
methods and standards are still in their early stages. Studies in AD 
have identified profiles of miRNAs in CSF that may distinguish 
patients from controls but have been inconsistent across studies 
(119–121). Levels of miRNA levels are affected by the presence of 
cells, so that careful standardization will be necessary for studies 
using CSF (121). Studies of miRNA are reviewed in more detail 
in this collection of reviews (122).
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Peripheral cells, such as mononuclear cells and lymphocytes, 
as well as platelets have been the subjects of many types of bio-
marker studies in AD. The nature of these studies and the types 
of biomarkers that have been sought are too diverse to be easily 
summarized here. Although an enormous number of markers 
and biological processes can be interrogated using cells, to date, 
no consistent biomarker profiles have emerged that were subse-
quently widely replicated.
vALiDATiNG AND UNDeRSTANDiNG 
BiOMARKeRS
The initial validation of biomarkers requires the development of 
quantitative, sensitive, and reliable assays, and identifying pre-
analytical and analytical factors that may influence the levels 
that are measured (123). As examples of pre-analytical factors, 
for Aβ, polypropylene collection tubes are required, whereas 
for alpha-synuclein, measuring the extent of contamination by 
hemoglobin is important (124). Effects of storage, freeze–thaw 
cycles, and sample handling need to be carefully determined. 
Assay performance metrics, the type of analytical platform to be 
used, preparation and use of analytical standards and biological 
replicates also need to be standardized. Appropriately scaled 
clinical studies aimed at determining cutoff points, sensitivity, 
and specificity need to be conducted. Depending on the proposed 
use of the biomarker, longitudinal studies and postmortem con-
firmation of pathological features of brain pathology may add 
credence to claims for sensitivity and specificity. Meta-analyses 
or pooled analyses of multi-center data can provide information 
about effects of age and APOE genotype on CSF biomarkers 
(65). Assays typically progress through different stages of 
qualification. Much effort has gone into comparisons of A-beta 
and tau assays, including round robin efforts, which also were 
recently applied to MS assays for A-beta (125), and international 
quality control efforts. Next-generation assays for A-beta42, tau, 
and P-tau may help to decrease variability and to develop rigor-
ous and standardized cutoff points that are readily applicable 
across laboratories. Understanding the phenomena that the 
biomarkers are measuring goes beyond these validation steps 
that have been outlined, and it is a critical step in determining 
the use of biomarkers, particularly regarding therapeutic stud-
ies. As a sobering observation, although increased CSF levels 
of tau and P-tau are routinely detected in AD, the mechanisms 
whereby these biomarkers are released into the CSF are not well 
understood.
There are many opportunities to study genetics in relation to 
biomarkers, some of which have been discussed earlier. Large-
scale studies of patients with inherited forms of early onset 
AD are helping to expand the map and timeline of biomarkers 
(126). Because age is the strongest risk factor for sporadic AD, 
it is important to continue to study how biomarkers and related 
brain processes change during aging. As an example, studies of 
Aβ metabolism using SILK have shown that there are marked 
changes in parameters related to production and clearance of Aβ 
from the CSF in association with aging (127).
TOwARD AN eXPANDeD SUiTe  
OF BiOMARKeRS
Biomarkers in biofluids have provided several important 
insights into AD, and currently have a role both in diagnosis 
and in the development of therapy. An attainable future goal is 
to improve and standardize current assays for Aβ, tau, and P-tau 
to permit routine and widespread clinical use. Progress will 
continue to be made in the development of assays to allow early 
and pre-symptomatic detection of AD to facilitate therapeutic 
studies (128). An ambitious goal will be to identify biomarkers 
that predict who is at risk for beginning to developing amyloid 
deposition in the brain before these deposits arise. In the area 
of diagnostics, the development of multi-analyte panels that 
are able to provide indices of non-AD degenerative disorders 
and important biological processes will remain an important 
area of research. As an illustrative example, a recent study of 
a nine analyte panel of CSF biomarkers had good differential 
diagnostic ability to distinguish between atypical movement 
disorders, PD and AD (129).
For clinical trials, a suite of biomarkers to evaluate amyloid 
processing exists, but markers related to oligomers remain 
elusive. Biomarkers that inform about target engagement for 
other therapeutic areas, for example, tau therapeutics, require 
further development. Prognostic, predictive, and companion 
biomarkers have not yet been identified and can be sought in the 
context of longitudinal studies. Relationships between biofluid 
markers, brain imaging, and cognitive testing will help to refine 
the roadmap of progression along the way to dementia in AD, 
especially during preclinical and prodromal stages. The poten-
tial for plasma biomarkers to provide screening, diagnostic, or 
prognostic tools merits continued study, but the design and 
validation of a plasma biomarker may be more complex than for 
a CSF biomarker.
The growth of research and development of new tech-
nologies gives hope that we may be able to develop a more 
comprehensive suite of biomarkers to build a detailed picture 
of the brain, that may integrate markers related to different 
cell types, important cellular structures such as synapses, 
biological processes such as transport, lipid metabolism, and 
exosome release, and effects of damage, oxidative stress, and 
inflammation. Progress in these areas holds the promise of 
greatly extending the reach of biofluid biomarkers for AD and 
related disorders.
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